IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
71.52 USD
+0.06 (+0.08%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 191 industry peers in the Health Care Equipment & Supplies industry. IRMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IRMD has a decent growth rate and is not valued too expensively. These ratings could make IRMD a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
IRMD had a positive operating cash flow in the past year.
In the past 5 years IRMD has always been profitable.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
IRMD has a better Return On Assets (19.41%) than 97.91% of its industry peers.
IRMD has a Return On Equity of 21.91%. This is amongst the best in the industry. IRMD outperforms 93.72% of its industry peers.
IRMD has a better Return On Invested Capital (19.30%) than 97.38% of its industry peers.
IRMD had an Average Return On Invested Capital over the past 3 years of 18.78%. This is significantly above the industry average of 8.46%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of IRMD (26.61%) is better than 94.76% of its industry peers.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
IRMD has a better Operating Margin (30.67%) than 97.38% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
IRMD has a better Gross Margin (76.96%) than 89.53% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
Compared to 5 years ago, IRMD has more shares outstanding
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 47.97 indicates that IRMD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 47.97, IRMD belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 47.97 |
ROIC/WACC2.22
WACC8.69%
2.3 Liquidity
IRMD has a Current Ratio of 8.78. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD's Current ratio of 8.78 is amongst the best of the industry. IRMD outperforms 90.05% of its industry peers.
IRMD has a Quick Ratio of 7.51. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.51, IRMD belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.25%, which is quite good.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.74%.
IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.71% yearly.
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
3.2 Future
The Earnings Per Share is expected to grow by 12.71% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.12% on average over the next years. This is quite good.
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.87%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
IRMD is valuated quite expensively with a Price/Earnings ratio of 40.18.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than 70.16% of the companies in the same industry.
When comparing the Price/Earnings ratio of IRMD to the average of the S&P500 Index (27.20), we can say IRMD is valued slightly more expensively.
A Price/Forward Earnings ratio of 34.12 indicates a quite expensive valuation of IRMD.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than the industry average as 71.73% of the companies are valued more expensively.
IRMD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.18 | ||
| Fwd PE | 34.12 |
4.2 Price Multiples
70.68% of the companies in the same industry are more expensive than IRMD, based on the Enterprise Value to EBITDA ratio.
72.77% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.24 | ||
| EV/EBITDA | 34.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IRMD may justify a higher PE ratio.
A more expensive valuation may be justified as IRMD's earnings are expected to grow with 12.71% in the coming years.
PEG (NY)2.8
PEG (5Y)2.89
EPS Next 2Y12.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a yearly dividend return of 0.89%, which is pretty low.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.69. IRMD pays more dividend than 93.19% of the companies in the same industry.
With a Dividend Yield of 0.89, IRMD pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.89% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.33% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.33%
EPS Next 2Y12.71%
EPS Next 3YN/A
NASDAQ:IRMD (9/17/2025, 10:38:52 AM)
71.52
+0.06 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.46%
Inst Owner Change1.21%
Ins Owners36.83%
Ins Owner Change0.67%
Market Cap909.73M
Analysts82.5
Price Target74.97 (4.82%)
Short Float %1.89%
Short Ratio3.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.89% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.33%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)0.43%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)4.6%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)6.12%
EPS beat(12)10
Avg EPS beat(12)7.27%
EPS beat(16)14
Avg EPS beat(16)11.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)0.01%
Revenue beat(8)3
Avg Revenue beat(8)-0.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.16%
Revenue beat(16)7
Avg Revenue beat(16)-0.07%
PT rev (1m)0%
PT rev (3m)3.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)6.63%
EPS NY rev (3m)6.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)2.84%
Revenue NY rev (3m)2.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.18 | ||
| Fwd PE | 34.12 | ||
| P/S | 11.72 | ||
| P/FCF | 68.24 | ||
| P/OCF | 33.52 | ||
| P/B | 9.65 | ||
| P/tB | 10.01 | ||
| EV/EBITDA | 34.79 |
EPS(TTM)1.78
EY2.49%
EPS(NY)2.1
Fwd EY2.93%
FCF(TTM)1.05
FCFY1.47%
OCF(TTM)2.13
OCFY2.98%
SpS6.1
BVpS7.41
TBVpS7.15
PEG (NY)2.8
PEG (5Y)2.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROCE | 24.39% | ||
| ROIC | 19.3% | ||
| ROICexc | 42.22% | ||
| ROICexgc | 45.68% | ||
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% | ||
| FCFM | 17.17% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1738.97% | ||
| Cap/Sales | 17.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.32% | ||
| Profit Quality | 64.54% | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 | ||
| Altman-Z | 47.97 |
F-Score4
WACC8.69%
ROIC/WACC2.22
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
Revenue Next Year11.87%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.02%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.2%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y79.39%
OCF growth 3Y31.53%
OCF growth 5Y20.16%